Spots Global Cancer Trial Database for asciminib
Every month we try and update this database with for asciminib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Frontline Asciminib Combination in Chronic Phase CML | NCT03906292 | Chronic Myeloid... | Imatinib Nilotinib 300 m... Dasatinib Asciminib | 18 Years - | University of Jena | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis | |
| ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor | NCT04216563 | Philadelphia Ch... | Asciminib | 18 Years - | M.D. Anderson Cancer Center | |
| Special Drug Use-results Surveillance of Scemblix Tablets | NCT05421091 | Chronic Myeloid... | Asciminib | - 99 Years | Novartis | |
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors | NCT04795427 | Leukemia, Chron... | asciminib best available ... | 18 Years - | Novartis | |
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT05143840 | Chronic Myeloid... Adult CML Leukemia, Myelo... Leukemia,Myeloi... | Asciminib Ascimininb + Ni... Asciminib + Ima... Asciminib + Das... | 18 Years - | Augusta University | |
| A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia | NCT06368414 | Chronic Myeloid... | Asciminib | 19 Years - | Korean Society of Hematology | |
| Special Drug Use-results Surveillance of Scemblix Tablets | NCT05421091 | Chronic Myeloid... | Asciminib | - 99 Years | Novartis | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| Asciminib RMP Study | NCT05943522 | Chronic Myeloid... | Asciminib | 18 Years - | Novartis | |
| Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | NCT06308588 | Philadelphia Ch... Acute Lymphobla... | Blinatumomab Asciminib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03578367 | CML Chronic Myeloge... Leukemia, Myelo... Hematologic Dis... | Asciminib add-o... Imatinib Nilotinib Asciminib singl... | 18 Years - | Novartis | |
| Asciminib RMP Study | NCT05943522 | Chronic Myeloid... | Asciminib | 18 Years - | Novartis | |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | NCT04971226 | Chronic Myeloid... | Imatinib Nilotinib Bosutinib Dasatinib Asciminib | 18 Years - | Novartis | |
| Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation | NCT06427811 | Philadelphia Ch... | Asciminib | 18 Years - | Novartis | |
| Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | NCT05143840 | Chronic Myeloid... Adult CML Leukemia, Myelo... Leukemia,Myeloi... | Asciminib Ascimininb + Ni... Asciminib + Ima... Asciminib + Das... | 18 Years - | Augusta University | |
| Frontline Asciminib Combination in Chronic Phase CML | NCT03906292 | Chronic Myeloid... | Imatinib Nilotinib 300 m... Dasatinib Asciminib | 18 Years - | University of Jena | |
| Managed Access Programs for ABL001, Asciminib | NCT04360005 | Chronic Myeloid... | Asciminib | 18 Years - 99 Years | Novartis | |
| ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor | NCT04216563 | Philadelphia Ch... | Asciminib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia | NCT06368414 | Chronic Myeloid... | Asciminib | 19 Years - | Korean Society of Hematology | |
| Asciminib Roll-over Study | NCT04877522 | Chronic Myeloge... Leukemia, Myelo... | Asciminib singl... Asciminib Imatinib Nilotinib Bosutinib Dasatinib | 18 Years - | Novartis | |
| A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | NCT02081378 | Chronic Myeloge... Philadelphia Ch... | Asciminib (ABL0... Nilotinib Imatinib Dasatinib | 18 Years - | Novartis | |
| Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France | NCT06092879 | Chronic Myeloid... | Asciminib | 18 Years - 99 Years | Novartis | |
| Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | NCT03106779 | Chronic Myeloge... | Asciminib Bosutinib | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
